The phase II WSG-ADAPT trial assessed the efficacy of 12 weeks of neoadjuvant trastuzumab emtansine or trastuzumab with endocrine therapy in ER+/HER2+ early breast cancer and demonstrated a pCR rate of only 15.1% following the chemotherapy-free approach of trastuzumab with endocrine therapy12. The gene discussed is ESR1; the disease is breast cancer.